Clinical Trial Update: A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating a shorter infusion protocol for ocrelizumab in primary progressive and relapsing multiple sclerosis has completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Ocrelizumab (ocrelizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2020-06-29